Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its price target increased by B. Riley from $5.00 to $6.00 in a research report sent to investors on Tuesday. They currently have a buy rating on the stock. B. Riley also issued estimates for Eyepoint Pharmaceuticals’ FY2020 earnings at ($0.23) EPS, FY2021 earnings at ($0.11) EPS, FY2022 earnings at $0.06 EPS and FY2023 earnings at $0.26 EPS.

A number of other equities research analysts also recently issued reports on EYPT. HC Wainwright reissued a buy rating and issued a $2.50 price target on shares of Eyepoint Pharmaceuticals in a research note on Tuesday, June 26th. Zacks Investment Research downgraded shares of Eyepoint Pharmaceuticals from a hold rating to a sell rating in a research note on Tuesday, July 10th. Finally, ValuEngine raised shares of Eyepoint Pharmaceuticals from a hold rating to a buy rating in a research note on Wednesday, September 19th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The stock has an average rating of Buy and an average price target of $5.40.

EYPT stock traded down $0.34 during trading on Tuesday, reaching $2.61. 64,093 shares of the stock were exchanged, compared to its average volume of 1,084,997. The company has a debt-to-equity ratio of 1.48, a current ratio of 1.84 and a quick ratio of 1.84. Eyepoint Pharmaceuticals has a 1 year low of $0.93 and a 1 year high of $3.94. The company has a market capitalization of $161.55 million, a PE ratio of -4.47 and a beta of 0.85.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its earnings results on Wednesday, September 12th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.08). The firm had revenue of $0.72 million for the quarter, compared to analysts’ expectations of $0.67 million. Eyepoint Pharmaceuticals had a negative return on equity of 301.45% and a negative net margin of 1,795.71%. Sell-side analysts forecast that Eyepoint Pharmaceuticals will post -0.42 EPS for the current year.

Several institutional investors have recently added to or reduced their stakes in EYPT. FineMark National Bank & Trust purchased a new stake in shares of Eyepoint Pharmaceuticals in the 2nd quarter valued at approximately $118,000. California Public Employees Retirement System acquired a new position in shares of Eyepoint Pharmaceuticals in the second quarter valued at approximately $135,000. Creative Planning acquired a new position in shares of Eyepoint Pharmaceuticals in the second quarter valued at approximately $162,000. Essex Investment Management Co. LLC acquired a new position in shares of Eyepoint Pharmaceuticals in the second quarter valued at approximately $170,000. Finally, Bard Associates Inc. acquired a new position in shares of Eyepoint Pharmaceuticals in the second quarter valued at approximately $189,000. 62.90% of the stock is currently owned by institutional investors and hedge funds.

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis.

Featured Story: What is the Dow Jones Industrial Average (DJIA)?

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.